Navigation Links
Enox Biopharma, Inc. Will Present at IN3 East Investment in Innovation Conference
Date:6/21/2011

VANCOUVER, British Columbia, June 21, 2011 /PRNewswire/ -- Enox Biopharma, Inc. CEO, John C. Rewcastle, Ph.D., will present at the IN3 East Investment in Innovation Conference on Wednesday, June 22 at 12:15 AM EST. The conference is being held at the Hyatt Regency Hotel in Boston.

The IN3 East meeting, hosted by Elsevier, is a medtech industry forum and networking meeting. The meeting is designed to provide exposure and constructive interaction between emerging medical innovation companies like Enox Biopharma and both venture capitalists and large device manufacturers.

Dr. Rewcastle will present Enox's technology whose foundation is the patent protected ability to embed nitric oxide into polymers which renders medical devices antimicrobial. He will also review recently filed intellectual property that expands Enox's technology to cover the wound healing space.

"One of the most significant problems facing the worldwide medical establishment is hospital acquired infections. In the United States alone, these infections drain an estimated $30-45 billion dollars per year. Enox is uniquely positioned to address this problem with its antimicrobial technology which utilizes nitric oxide as the mechanism of action. Nitric oxide is an ideal antimicrobial agent as it is very effective but does not have resistance issues like antibiotics do."

"The IN3 East Conference represents a great opportunity," continued Rewcastle. "Enox will be attractive to both the venture capitalists and potential strategic partners in attendance. Our breakthrough technology has the potential of meeting the needs of hospitals worldwide who are currently underserved by existing infection prevention technology. I anticipate a positive response to our presentation and presence at this event."

About Enox Biopharma, Inc.

Enox Biopharma, Inc. is an emerging biotechnology company with proprietary methods to sequester nitric oxide (NO) into polymers. The innate i
'/>"/>

SOURCE Enox Biopharma, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. Enox Biopharma, Inc. Will Be Granted a Patent for the Delivery of Therapeutic Agents From Within Medical Devices
2. PDL BioPharma, Inc. Prices Offering of $135.0 Million of Convertible Senior Notes Due 2015
3. Plato BioPharma, Inc. Sponsors Novel Disease Model Award
4. Enox Biopharma, Inc. to Present at IN3 West Investment in Innovation Conference.
5. Plato BioPharma, Inc Appoints New Board Member
6. Enox Biopharma, Inc. to Present at OneMedForum Emerging Company Finance Conference.
7. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Receives New Research Grant From Hong Kong Innovation and Technology Commission
8. Berger & Montague, P.C., Files Class Action Against Hemispherx Biopharma, Inc. Extending the End of the Class Period to December 1, 2009, When the Company Announced That the FDA Found No Evidence of Efficacy of Its Drug
9. Pangu BioPharma, aTyr Pharmas Subsidiary in Hong Kong, Files Three Patent Applications
10. DOR BioPharma, Inc. Executes $400,000 Equity Investment Agreement With Numoda Corporation
11. CB1400, Patented by Canopus BioPharma, Enters Phase II Clinical Trials for the Prevention of Mucositis in Patients With Cancer of the Head and Neck
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... , Jan. 15, 2014  Valeant Pharmaceuticals International, Inc. (NYSE: ... the applicable waiting period under the Hart-Scott-Rodino Antitrust Improvements ... announced tender offer by its indirect wholly-owned subsidiary, Sapphire ... of common stock of Solta Medical, Inc. (NASDAQ: ...
(Date:1/15/2014)...  Zafgen, Inc., a leading biopharmaceutical company dedicated to ... today announced initial results from its Phase 2a ... aminopeptidase 2 (MetAP2), in patients with Prader-Willi syndrome ... results showed improvements in body weight, hunger-related behaviors, ...
(Date:1/14/2014)... Jan. 14, 2014  Luminex Corporation (Nasdaq: LMNX ) ... fourth quarter of 2013 on Monday, February 3, 2014. A ... the close of trading. (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ... discuss the operating highlights and financial results for the fourth ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
(Date:4/18/2014)... did it make you feel? According to psychologists, remembering ... as how sad you were or how embarrassed you ... can,t stop thinking about it. , When these ... the memories, rather than how you felt, is a ... effects of these memories, a new study suggests. , ...
(Date:4/18/2014)... A discovery by Northwestern Medicine scientists could lead to ... scarring in people with scleroderma. , Fibrosis, or ... tightening of the skin and lungs can lead to ... The concept for new therapeutic options centers on findings ... Medicine-Rheumatology, who identified the role that a specific protein ...
(Date:4/17/2014)... One of the most popular vaccine brands for children ... may be overlooking some cost factors when choosing vaccines, ... expensive option, according to a new study by University ... administer can be driven by numerous factors," says Sheldon ... professor of computer science and of mathematics at the ...
(Date:4/17/2014)... MANHASSET, NY In a review published in the ... MD, president of The Feinstein Institute for Medical Research, ... the medical community,s approach to treating sepsis, ... 200,000 Americans. , Sepsis occurs when molecules released into ... inflammation throughout the body. Inflammation is necessary for maintaining ...
(Date:4/17/2014)... million older Americans suffer from depression, often brought on ... research a project that followed the lives of ... found that Internet use among the elderly can reduce ... , "That,s a very strong effect," said Shelia Cotten, ... and media who led the project. "And it all ...
Breaking Medicine News(10 mins):Health News:New study suggests a better way to deal with bad memories 2Health News:New study suggests a better way to deal with bad memories 3Health News:New clues on tissue scarring in scleroderma 2Health News:Study recalculates costs of combination vaccines 2Health News:Feinstein Institute researcher publishes new perspective on sepsis 2Health News:Internet use can help ward off depression among elderly 2
... Case Studies in the Management of PK/PD Data Will be Presented ... ... France, MOUNTAIN VIEW, Calif., Sept. 25 Pharsight,Corporation (OTC ... optimizing clinical drug development, today,announced that Dan Weiner, Ph.D., Senior Vice ...
... Call it Quits collaborative launches new Minnesota Clinic Fax Referral ... ... 25 Call it Quits,-- a newly named collaboration among Minnesota,s major ... it easier,for physicians and other healthcare providers to help their patients who,want ...
... the Cure(TM) Kicks Off October 1; Join the Breast ... Cancer Movement by Wearing Pink In October, DALLAS, Sept. ... together to increase awareness of breast cancer,a disease that without a ... you can join them. (Logo: http://www.newscom.com/cgi-bin/prnh/20070122/NYM084LOGO ) The ...
... Australian researcher has completed some pioneering work which is ... , Professor Patrick Tams 27-year exploration has mapped ... embryos. It reveals how cells direct themselves to ... He was (today) awarded recognition at a national conference ...
... PGL; Nasdaq: PGLA) announced today that its investigational,anti-cancer ... by the U.S. Food,and Drug Administration (FDA). The ... for the prevention of tumor recurrence following curative ... liver,cancer). Under the FDA Modernization Act of ...
... ARBOR, Mich. -- Despite decades of advances in diabetes ... likely than whites to have their blood sugar under ... nationally representative study finds. That puts them at a ... foot amputation and other long-term diabetes complications. , ...
Cached Medicine News:Health News:Pharsight to Host European Software Conference 2Health News:Health Organizations Join Forces Around Quit-Smoking Help 2Health News:Celebrities Pledge to Wear Pink, End Breast Cancer Forever With Susan G. Komen for the Cure 2Health News:Celebrities Pledge to Wear Pink, End Breast Cancer Forever With Susan G. Komen for the Cure 3Health News:Explorer completes the map ... for the body's blueprint 2Health News:US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer 2Health News:US FDA Fast Tracks PI-88 for the Treatment of Post Resection Liver Cancer 3Health News:Older blacks and Latinos still lag whites in controlling diabetes 2Health News:Older blacks and Latinos still lag whites in controlling diabetes 3Health News:Older blacks and Latinos still lag whites in controlling diabetes 4Health News:Older blacks and Latinos still lag whites in controlling diabetes 5
The best combination with the Haag-Streit 900 Slitlamps. For examination of the entire fundus, the vitreous and the iridocorneal angle. For newly born children. 10 mm internal diameter of the cornea ...
The best combination with the Haag-Streit 900 Slitlamps. For examination of the entire fundus, the vitreous and the iridocorneal angle. The classic Goldmann Glass....
For the binocular slit observation of the pupil, the macula, its surroundings out to 30 as well as the central vitreous body sections. Easy to use, lightweight glass provides a direct image....
... philosophy of the Quad 4™ Intramedullary Nailing ... that could be used for the widest ... of the system were to minimize the ... inventory, with one system that could address ...
Medicine Products: